Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZA98D
|
|||
| Drug Name |
ARGX-113
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myasthenia gravis [ICD-11: 8C6Y] | Phase 3 | [1] | |
| Company |
Argenx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neonatal Fc receptor (FCGRT) | Target Info | Antagonist | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03770403) A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+). U.S. National Institutes of Health. | |||
| REF 2 | Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.